For example, dulaglutide includes the same GLP-1 variant as Exendin-4-Fc and produces significant weight reduction in db/db mice, but not in humans
According to NICE guidelines, it can be prescribed for adults with a BMI of 35 or above who have at least one obesity-related health condition (such as hypertension, sleep apnoea, or joint problems)
GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda) are licensed specifically for weight management, while semaglutide (Ozempic) is licensed only for type 2 diabetes treatment
Nausea, vomiting, and diarrhoeareported by a substantial proportion of patients, especially during treatment initiationresult in the loss of not only water but also essential electrolytes, particularly sodium, potassium, and chloride